
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) – HC Wainwright decreased their FY2026 earnings per share estimates for Structure Therapeutics in a report released on Thursday, November 12th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($2.18) per share for the year, down from their prior forecast of ($1.84). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2026 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.63) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at ($2.54) EPS.
A number of other analysts also recently weighed in on GPCR. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp restated a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings upgraded shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Wall Street Zen lowered shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.91.
Get Our Latest Research Report on GPCR
Structure Therapeutics Stock Down 2.2%
Shares of GPCR stock opened at $18.17 on Monday. Structure Therapeutics has a 1 year low of $17.81 and a 1 year high of $94.90. The firm’s fifty day simple moving average is $26.86 and its 200 day simple moving average is $45.36.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15).
Institutional Investors Weigh In On Structure Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in GPCR. Wellington Management Group LLP increased its position in shares of Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after purchasing an additional 119,146 shares in the last quarter. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 5.2% in the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after buying an additional 264,833 shares in the last quarter. Orbimed Advisors LLC boosted its position in Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after buying an additional 313,600 shares in the last quarter. Siren L.L.C. grew its stake in Structure Therapeutics by 23.2% during the first quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after buying an additional 250,000 shares during the last quarter. Finally, SEB Asset Management AB bought a new stake in Structure Therapeutics during the first quarter worth about $11,811,000. Institutional investors and hedge funds own 91.78% of the company’s stock.
Structure Therapeutics Company Profile
Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.
Featured Articles
- Five stocks we like better than Structure Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
